Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at Barclays Global Healthcare Conference Transcript

Mar 15, 2023 / 06:35PM GMT
Release Date Price: $45.16 (-2.59%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Perfect. Good afternoon. Welcome to Barclays Global Healthcare Conference in Miami. Do e-mail us or associates to self-online as well on Bloomberg, and if you have questions. My name is Peter Lawson. I'm one of the mid-cap biotech analyst at Barclays, and really delighted, as I have up on stage with us management from Blueprint Medicines and so we've got Mike Landsittel, CFO; and Becker Hewes, Chief Medical Officer.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

And I guess first kind of question is just around how we should think about -- how quickly you can get to market post PDUFA kind of thing?

Michael Landsittel
Blueprint Medicines Corporation - CFO

Yes. So thanks, Peter. First of all, thanks for having us. And on behalf of Blueprint, it's great to participate in this conference. With respect to AYVAKIT, so we have a PDUFA date scheduled for May 22 of this year, so that's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot